Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 02, 2009
Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
Pfizer has previously touted PF-02341066 as "the first agent in clinical development that selectively targets a unique genetic feature of cancer cells." The drug is currently in Phase III trials, while Abbott is in the process of designing validating trials for a companion test with the capability to detect ALK gene rearrangements.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Q&A: Pfizer's Dx Division Head Discusses Pharma Giant's Focus on Personalized Medicine
September 9, 2009 / Pharmacogenomics Reporter - GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 1, 2011 / PCR Insider